NEW YORK (GenomeWeb News) - Invitrogen said today it will buy primary cell provider CellzDirect for around $57 million in cash in an effort to expand its cellular analysis business.
 
CellzDirect’s human hepatocyte-based cell products and services are used in drug testing, particularly for predicting the effect of compounds on enzymatic metabolism in the liver.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.